(Q37957629)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094711%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094711%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094711%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Harald Sourij

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094711%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

1 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094711%20AND%20SRC:MED&resulttype=core&format=json

Current cardiology reports

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094711%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094711%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

59-69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094711%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094711%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11886-011-0229-7

16 January 2020

exact match

0 references

cites work

Diabetes mellitus, fasting glucose, and risk of cause-specific death

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Therapeutic roles of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Determining the most appropriate components for a composite clinical trial outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

The ClinicalTrials.gov results database--update and key issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Industry-sponsored clinical research: a broken system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Revisiting the rosiglitazone story--lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

The importance of independent academic statistical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Clinical trial registration: a statement from the International Committee of Medical Journal Editors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0229-7

Collaborative clinical trials

21 January 2018

1 reference

12 December 2020

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

1 reference

12 December 2020

New FDA regulation to improve safety reporting in clinical trials

1 reference

12 December 2020

The rosiglitazone story--lessons from an FDA Advisory Committee meeting

1 reference

12 December 2020

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events

1 reference

12 December 2020

Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule

1 reference

12 December 2020

Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone

1 reference

12 December 2020

10.1007/S11886-011-0229-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22094711%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference